Diagnostic and therapeutic challenges.
Kaiser Permanente Medical Group, Walnut Creek, California, USA.
Sam
S
Yang
Sidhiporn
S
Borirakchanyavat
Brian T
BT
Chan-Kai
J Timothy
JT
Stout
Arthur D
AD
Fu
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D004596:Electroretinography; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D009755:Night Blindness / Q000175:diagnosis; D012163:Retinal Detachment / Q000175:diagnosis; D055213:Retinal Pigment Epithelium / Q000473:pathology; D012171:Retinal Vessels / Q000002:abnormalities* / Q000473:pathology; D012173:Retinitis / Q000175:diagnosis* / Q000188:drug therapy; D012174:Retinitis Pigmentosa / Q000175:diagnosis* / Q000188:drug therapy; D013684:Telangiectasis / Q000175:diagnosis* / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014794:Visual Fields
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab